FDA halts testing of Idenix drug for hepatitis
Idenix Pharmaceuticals Inc., a Cambridge-based drug company, said yesterday that federal regulators suspended testing of its hepatitis C drug, resulting in a 38 percent drop in the company's stock. (Full article: 493 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
